[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBolE1La7Hy4uRZDFX5G2z0BKFBrPXWwLHZxVGXtsNbE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"National Cheng Kung University",[4],58,false,9,0,5594,56,[13,16,18,21,23,25,27,30],{"name":14,"count":15},"Chronic Kidney Diseases",4,{"name":17,"count":15},"Neck Pain",{"name":19,"count":20},"Exercise Training",3,{"name":22,"count":20},"Rehabilitation",{"name":24,"count":20},"Depression",{"name":26,"count":20},"Autism Spectrum Disorder",{"name":28,"count":29},"Stroke",2,{"name":31,"count":29},"Virtual Reality",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,72,90,116],{"intervention":42,"totalTrials":43,"cells":44},"cefuroxime",1,{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":55},{"trials":46,"activeCount":9},[],{"trials":48,"activeCount":9},[],{"trials":50,"activeCount":9},[],{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[],{"trials":56,"activeCount":9},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":70},"NCT01237730","Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy","UNKNOWN",[39],"2011-07","2011-08","2010-07",100,[67,68,69],"The Patients Who Receive Percutaneous Endoscopic Gastrostomy","Peristomal Wound Infection After the Operation of PEG","Prophylactic Antibiotics Before PEG",[42,71],"Tailored antibiotic",{"intervention":71,"totalTrials":43,"cells":73},{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":84},{"trials":75,"activeCount":9},[],{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[86],{"nctId":58,"briefTitle":59,"status":60,"phases":87,"primaryCompletion":62,"completion":63,"start":64,"enrollment":65,"conditions":88,"interventions":89},[39],[67,68,69],[42,71],{"intervention":91,"totalTrials":43,"cells":92},"Levetiracetam Oral Product",{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":103},{"trials":94,"activeCount":9},[],{"trials":96,"activeCount":9},[],{"trials":98,"activeCount":9},[],{"trials":100,"activeCount":9},[],{"trials":102,"activeCount":9},[],{"trials":104,"activeCount":9},[105],{"nctId":106,"briefTitle":107,"status":60,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT04858841","Post-stroke Epilepsy: Primary Prophylaxis Study",[39],"2023-07-31","2020-08-01",180,[113],"Middle Cerebral Artery Stroke",[91,115],"Perampanel Oral Product",{"intervention":115,"totalTrials":43,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[],{"trials":127,"activeCount":9},[],{"trials":129,"activeCount":9},[130],{"nctId":106,"briefTitle":107,"status":60,"phases":131,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":132,"interventions":133},[39],[113],[91,115]]